Exploring racial differences in outcome and treatment for metastatic colorectal cancer: Results from a large prospective observational cohort study (BRiTE)

Cancer

Volumn 118, Issue 4, 2012, Pages 1083-1090

  Polite, Blase N ^a   Sing, Amy ^b   Sargent, Daniel J ^c   Grothey, Axel ^c   Berlin, Jordan ^d   Kozloff, Mark ^a   Feng, Shibao ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b GENENTECH INC   (United States)

^c MAYO CLINIC ROCHESTER   (United States)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

African Americans; chemotherapy; colorectal neoplasms; comorbidities; health care disparities

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AFRICAN AMERICAN; ARTERY THROMBOSIS; ARTICLE; BLEEDING DISORDER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CAUCASIAN; COLORECTAL CANCER; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIGESTIVE SYSTEM PERFORATION; DISEASE EXACERBATION; DRUG EFFECT; DRUG SAFETY; FEMALE; HEALTH CARE DISPARITY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METASTASIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIMARY HEALTH CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RACE DIFFERENCE; TREATMENT DURATION; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM; AGED; ARTERIAL THROMBOEMBOLISM; BLEEDING; DISEASE SEVERITY; DRUG EFFICACY; INCIDENCE; METASTATIC COLORECTAL CANCER; SURVIVAL TIME; TREATMENT RESPONSE;

AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COLORECTAL NEOPLASMS; DRUG THERAPY, COMBINATION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OUTCOME ASSESSMENT (HEALTH CARE); PROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; UNITED STATES;

EID: 80054936950     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26394     Document Type: Article

References (37)

1. Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Database: IncidenceâSEER 17 Regs Limited-Use + Hurricane Katrina Impacted Louisiana Cases [released April 2008; based on the November 2007 submission; 1973-2005 varying]. Bethesda, MD: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2008. Accessed February 15, 2011.
2. American Cancer Society. Colorectal Cancer Facts & Figures for African Americans, 2008-2010. Atlanta, GA: American Cancer Society; 2008.
3. Altekruse SF, Kosary CL, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2007 [based on the November 2009 SEER data submission, posted to the SEER web site 2010]. Bethesda, MD: National Cancer Institute; 2010. Accessed February 15, 2011.
4. Mayberry RM, Coates RJ, Hill HA, et al. Determinants of black/white differences in colon cancer survival. J Natl Cancer Inst. 1995; 87: 1686-1693.
5. Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM,. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol. 2009; 27: 4109-4115.
6. Alexander D, Jhala N, Chatla C, et al. High-grade tumor differentiation is an indicator of poor prognosis in African Americans with colonic adenocarcinomas. Cancer. 2005; 103: 2163-2170.
7. Ashktorab H, Smoot DT, Carethers JM, et al. High incidence of microsatellite instability in colorectal cancer from African Americans. Clin Cancer Res. 2003; 9: 1112-1117.
8. Ashktorab H, Smoot DT, Farzanmehr H, et al. Clinicopathological features and microsatellite instability (MSI) in colorectal cancers from African Americans. Int J Cancer. 2005; 116: 914-919.
9. Baldwin LM, Dobie SA, Billingsley K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst. 2005; 97: 1211-1220.
10. Kumar K, Brim H, Giardiello F, et al. Distinct BRAF (V600E) and KRAS mutations in high microsatellite instability sporadic colorectal cancer in African Americans. Clin Cancer Res. 2009; 15: 1155-1161.
11. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D,. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005; 294: 1765-1772.
12. Obeidat NA, Pradel FG, Zuckerman IH, et al. Racial/ethnic and age disparities in chemotherapy selection for colorectal cancer. Am J Manag Care. 2010; 16: 515-522.
13. Dignam JJ, Colangelo L, Tian W, et al. Outcomes among African-Americans and Caucasians in colon cancer adjuvant therapy trials: findings from the National Surgical Adjuvant Breast and Bowel Project. J Natl Cancer Inst. 1999; 91: 1933-1940.
14. Dignam JJ, Ye Y, Colangelo L, et al. Prognosis after rectal cancer in blacks and whites participating in adjuvant therapy randomized trials. J Clin Oncol. 2003; 21: 413-420.
15. Yothers Y, Blackstock W, Wolmark N, et al. Outcomes in white (W) patients (pts) and those of African (A) descent receiving adjuvant therapy for colon cancer (CC) [abstract]. J Clin Oncol. 2007; 25 (18S; June 20 suppl). Abstract 4017.
16. Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst. 2007; 99: 1232-1239.
17. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335-2342.
18. Brancati FL, Kao WH, Folsom AR, Watson RL, Szklo M,. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA. 2000; 283: 2253-2259.
19. Hajjar I, Kotchen TA,. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003; 290: 199-206.
20. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care. 1998; 21: 518-524.
21. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the US: 1990-1998. Diabetes Care. 2000; 23: 1278-1283.
22. Grothey A, Sugrue MM, Purdie DM, et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). J Clin Oncol. 2008; 26: 5326-5334.
23. McCollum AD, Catalano PJ, Haller DG, et al. Outcomes and toxicity in African-American and Caucasian patients in a randomized adjuvant chemotherapy trial for colon cancer. J Natl Cancer Inst. 2002; 94: 1160-1167.
24. Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL,. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst. 2009; 101: 984-992.
25. Beart RW, Steele GD Jr, Menck HR, Chmiel JS, Ocwieja KE, Winchester DP,. Management and survival of patients with adenocarcinoma of the colon and rectum: a national survey of the Commission on Cancer. J Am Coll Surg. 1995; 181: 225-236.
26. Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK,. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. Arch Intern Med. 2002; 162: 1985-1993.
27. Cronin DP, Harlan LC, Potosky AL, Clegg LX, Stevens JL, Mooney MM,. Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer. Am J Gastroenterol. 2006; 101: 2308-2318.
28. Du XL, Fang S, Vernon SW, et al. Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer. 2007; 110: 660-669.
29. Marcella S, Miller JE,. Racial differences in colorectal cancer mortality. The importance of stage and socioeconomic status. J Clin Epidemiol. 2001; 54: 359-366.
30. Roetzheim RG, Pal N, Gonzalez EC, Ferrante JM, Van Durme DJ, Krischer JP,. Effects of health insurance and race on colorectal cancer treatments and outcomes. Am J Public Health. 2000; 90: 1746-1754.
31. Schrag D, Rifas-Shiman S, Saltz L, Bach PB, Begg CB,. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002; 20: 3999-4005.
32. Du XL, Meyer TE, Franzini L,. Meta-analysis of racial disparities in survival in association with socioeconomic status among men and women with colon cancer. Cancer. 2007; 109: 2161-2170.
33. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009; 27: 3677-3683.
34. Griggs JJ, Sorbero ME, Stark AT, Heininger SE, Dick AW,. Racial disparity in the dose and dose intensity of breast cancer adjuvant chemotherapy. Breast Cancer Res Treat. 2003; 81: 21-31.
35. Mattison LK, Fourie J, Desmond RA, Modak A, Saif MW, Diasio RB,. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res. 2006; 12: 5491-5495.
36. Marsh S, Ameyaw MM, Githang'a J, Indalo A, Ofori-Adjei D, McLeod HL,. Novel thymidylate synthase enhancer region alleles in African populations [serial online]. Hum Mutat. 2000; 16: 528.
37. DeNavas-Walt C, Proctor BD, Hill Lee C,. US Census Bureau Current Population Report P60-229. Income, Poverty, and Health Insurance Coverage in the United States, 2004. Washington, DC: US Government Printing Office; 2005.